Strategies to enhance CAR-T persistence

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yue, An, Lingna, Huang, Ruihao, Xiong, Jingkang, Yang, Haoyu, Wang, Xiaoqi, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685914/
https://www.ncbi.nlm.nih.gov/pubmed/36419115
http://dx.doi.org/10.1186/s40364-022-00434-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685914/
https://www.ncbi.nlm.nih.gov/pubmed/36419115
http://dx.doi.org/10.1186/s40364-022-00434-9

Ejemplares similares